M. Wessels, V. Mahajan, S. Boßhammer, G. Raabe, H.-J. Gais
FULL PAPER
259 (15), 244 (10), 212 (18), 199 (10). C26H33NOSSi (435.69): calcd.
C 71.67, H 7.63, N 3.21; found C 72.05, H 7.28, N 3.21.
Me), 1.90–2.00 (m, 1 H, CCH2), 2.20 (s, 3 H, Me), 2.21–2.34 (m,
1 H, CCH2), 2.58 (dd, J = 14.0, 2.8 Hz, 1 H, CH2Ar), 2.85 (dd, J
= 14.0, 11.8 Hz, 1 H, CH2Ar), 3.06–3.15 (m, 1 H, CHS), 3.39–3.45
(m, 1 H, NCH2), 3.61–3.68 (m, 1 H, NCH2), 6.75 (s, 2 H, Ph),
7.55–7.61 (m, 2 H, Ph), 7.83–7.87 (m, 1 H, Ph), 8.13–8.18 (m, 1 H,
Ph) ppm. 13C NMR (100 MHz, CDCl3): δ = 2.8 (d), 20.3 (d), 21.1
(d), 26.2 (u), 26.8 (u), 30.1 (u), 43.9 (u), 60.8 (d), 129.4 (d), 129.4
(d), 130.4 (u), 130.8 (d), 132.5 (d), 136.2 (u), 137.0 (u), 137.0 (d),
(+)-(1S,6S)-6-Benzyl-1-(2-methylphenyl)-3,4,5,6-tetrahydro-1λ4-1,2-
thiazine 1-Oxide (20): Treatment of the sulfoximine 4 (646 mg,
2.26 mmol) with MeI (420 mg, 2.94 mmol) as described in GP 2
and chromatography (EtOAc/MeOH 9:1) gave the sulfoximine 20
(466 mg, 69%) with Ն98% de (1H NMR, o,oЈ-Ph) as a colorless
oil; Rf = 0.62 (EtOAc/MeOH 9:1). [α]D = +35.7 (c = 1.00 in
CH2Cl2). 1H NMR (500 MHz, CDCl3): δ = 1.73–1.91 (m, 2 H,
CH2CH2CH2), 2.07–2.14 (m, 1 H, CCH2), 2.16–2.26 (m, 1 H,
CCH2), 2.67 (dd, J = 14.0, 9.8 Hz, 1 H, CH2Ph), 2.84 (s, 3 H, Me),
2.84 (dd, J = 14.0, 4.6 Hz, 1 H, CH2Ph), 3.35 (dddd, J = 12.5, 9.2,
4.6, 4.2 Hz, 1 H, CHS), 3.41–3.47 (m, 1 H, NCH2), 3.59–3.66 (m,
1 H, NCH2), 6.91–6.94 (m, 2 H, Ph), 7.10–7.19 (m, 3 H, Ph), 7.27–
7.34 (m, 2 H, Ph), 7.42–7.46 (m, 1 H, Ph), 8.07–8.11 (m, 1 H,
Ph) ppm. 13C NMR (125 MHz, CDCl3): δ = 20.8 (d), 25.6 (u), 27.3
(u), 37.4 (u), 43.7 (u), 59.2 (d), 126.3 (d), 126.6 (d), 128.4 (d), 129.0
142.0 (u), 142.6 (u) ppm. IR (KBr): ν = 3448 (w), 3054 (w), 2943
˜
(s), 2851 (s), 1613 (w), 1579 (w), 1560 (w), 1481 (m), 1455 (m), 1420
(m), 1381 (w), 1349 (w), 1285 (m), 1248 (s), 1206 (s), 1176 (m),
1156 (m), 1117 (s), 1065 (m), 1044 (m), 1000 (m), 896 (m), 847 (s),
806 (s) cm–1. MS (EI, 70 eV): m/z (%) = 399 [M]+ (3), 385 (13), 384
(41), 327 (16), 326 (70), 202 (51), 191 (28), 182 (43), 167 (27), 159
(15), 134 (11), 133 (100), 131 (10), 119 (13), 117 (12), 105 (13), 91
(15), 70 (41). C23H33NOSSi (399.68): calcd. C 69.12, H 8.32, N
3.50; found C 68.83, H 8.66, N 3.38.
(d), 131.2 (d), 133.0 (d), 133.1 (d), 134.5 (u), 136.5 (u), 138.1 (+)-(1S,6S)-1-[2,6-Bis(trimethylsilylphenyl)]-6-(2,4,6-trimethylbenz-
(u) ppm. IR (capillary): ν = 3060 (m), 3026 (m), 3002 (w), 2927 (s),
yl)-3,4,5,6-tetrahydro-1λ4-1,2-thiazine 1-Oxide (24): Treatment of
˜
2847 (m), 1496 (m), 1471 (m), 1454 (s), 1349 (w), 1272 (m), 1247 the sulfoximine 22 (272 mg, 0.68 mmol) and ClSiMe3 (80 mg,
(s), 1232 (s), 1208 (s), 1193 (s), 1159 (m), 1138 (s), 1113 (s), 1076 0.75 mmol) as described in GP 2 and chromatography (EtOAc/n-
(m), 1059 (m), 1036 (w), 1003 (m), 930 (w), 898 (m), 874 (w), 842 hexane 1:1) gave the sulfoximine 24 (193 mg, 60%) with Ն98% de
(m), 824 (m), 808 (m) cm–1. MS (EI, 70 eV): m/z(%) = 299 [M]+
(1H NMR, C6H2Me) as a colorless solid; Rf = 0.80 (EtOAc/n-hex-
1
(6), 161 (12), 160 (100), 139 (26), 117 (13), 111 (17), 91 (49), 77 (19), ane 1:1); m.p. 56 °C. [α]D = +2.4 (c = 0.98 in CH2Cl2). H NMR
65 (10). HRMS for C18H21NOS [M]+: calcd. 299.134387; found
299.134297. C18H21NOS (299.13): calcd. C 72.20, H 7.07, N 4.68;
found C 71.82, H 7.25, N 5.12.
(400 MHz, CDCl3): δ = 0.46 (s, 9 H, SiMe3), 0.46 (s, 9 H, SiMe3),
1.58–1.88 (m, 1 H, CH2CH2CH2), 1.80 (s, 6 H, Me), 1.84–2.04 (m,
2 H, CCH2, CH2CH2CH2), 2.14 (dd, J = 13.7, 1.9 Hz, 1 H,
CH2Ar), 2.18 (s, 3 H, Me), 2.28–2.40 (m, 1 H, CCH2), 2.68 (dd, J
= 13.7, 11.8 Hz, 1 H, CH2Ar), 2.78–2.87 (m, 1 H, CHS), 3.42–3.48
(m, 1 H, NCH2), 3.74–3.83 (m, 1 H, NCH2), 6.72 (s, 2 H, Ph),
7.53–7.57 (t, J = 7.4 Hz, 1 H, Ph), 7.93 (dd, J = 7.4, 1.3 Hz, 1 H,
Ph), 7.97 (dd, J = 7.4, 1.3 Hz, 1 H, Ph) ppm. 13C NMR (100 MHz,
CDCl3): δ = 4.3 (d), 4.39 (d), 20.1 (d), 21.1 (d), 24.5 (u), 26.4 (u),
30.1 (u), 43.0 (u), 60.3 (d), 129.4 (d), 130.6 (u), 130.8 (d), 136.0 (u),
136.9 (u), 137.9 (d), 142.2 (u), 144.2 (u), 145.8 (u) ppm. IR (KBr):
(+)-(1S,6S)-1-(2-Methylphenyl)-6-(2,4,6-trimethylbenzyl)-3,4,5,6-
tetrahydro-1λ4-1,2-thiazine 1-Oxide (21): Treatment of the sulfox-
imine 5 (440 mg, 1.30 mmol) with MeI (210 mg, 1.48 mmol) as de-
scribed in GP 2 and chromatography (EtOAc/MeOH 9:1) gave the
sulfoximine 21 (315 mg, 71%) with Ն98% de (1H NMR, o,oЈ-Ph)
as a colorless solid; Rf = 0.57 (EtOAc/MeOH 9:1); m.p. 124 °C.
1
[α]D = +33.4 (c = 1.2 in CH2Cl2). H NMR (500 MHz, CDCl3): δ
= 1.71–1.85 (m, 2 H, CH2CH2CH2), 1.95 (s, 6 H, Me), 1.99–2.06
(m, 1 H, CCH2), 2.19 (s, 3 H, Me), 2.25–2.35 (m, 1 H, CCH2), 2.63
(dd, J = 14.3, 3.0 Hz, 1 H, CH2Ar), 2.86 (dd, J = 14.1, 11.0 Hz, 1
H, CH2Ar), 2.86 (s, 3 H, Me), 3.19 (dddd, J = 12.6, 4.1, 11.1,
3.1 Hz, 1 H, CHS), 3.45 (ddt, J = 12.8, 4.3, 2.2 Hz, 1 H, NCH2),
3.64 (dt, J = 13.1, 4.0 Hz, 1 H, NCH2), 6.74 (s, 2 H, Ph), 7.32–7.35
(m, 1 H, Ph), 7.37–7.42 (m, 1 H, Ph), 7.48–7.53 (m, 1 H, Ph), 8.19–
8.23 (m, 1 H, Ph) ppm. 13C NMR (125 MHz, CDCl3): δ = 20.1 (d),
21.0 (d), 21.3 (d), 26.3 (u), 27.3 (u), 30.2 (u), 44.1 (u), 58.4 (d),
126.6 (d), 129.4 (d), 130.5 (u), 131.9 (d), 133.4 (d), 133.6 (d), 134.1
ν = 3447 (w), 2946 (s), 2856 (m), 1614 (w), 1464 (m), 1383 (w),
˜
1340 (w), 1244 (s), 1204 (s), 1177 (w), 1145 (m), 1115 (s), 1083 (w),
1066 (w), 1043 (w), 998 (w), 892 (m), 847 (s), 805 (m) cm–1. MS
(EI, 70 eV): m/z (%) = 471 [M]+ (3), 458 (20), 457 (40), 456 (100),
399 (14), 398 (47), 269 (11), 254 (15), 239 (13), 202 (39), 133 (51),
73 (28), 45 (22). C26H41NOSSi2 (471.86): calcd. C 66.18, H 8.76, N
2.97; found C 65.81, H 8.69, N 2.67.
Synthesis of the o-Lithiosulfoximine 23 from the Bissilane 24 and Its
Deuteration: Treatment of the bissilane 24 (44 mg, 0.09 mmol) with
nBuLi (0.06 mL of 1.60 m in n-hexane, 0.10 mmol) as described in
GP 2, 10 min stirring at room temperature, and addition of
(u), 136.2 (u), 136.9 (u), 138.9 (u) ppm. IR (KBr): ν = 3056 (w),
˜
3011 (w), 2929 (s), 2851 (s), 2732 (w), 2683 (w), 2246 (w), 1610 (w),
1593 (w), 1570 (w), 1447 (s), 1379 (m), 1352 (w), 1247 (s), 1209 (s), CH3CO2D (0.01 mL of 17 m in THF, 0.23 mmol) at –78 °C gave
1192 (s), 1177 (s), 1156 (s), 1116 (s), 1058 (s), 1033 (m), 1001 (m),
896 (s), 878 (m), 855 (s), 834 (s), 807 (s) cm–1. MS (EI, 70 eV): m/z
(%) = 341 [M]+ (15), 221 (13), 202 (54), 173 (13), 159 (13), 157 (10),
139 (70), 134 (11), 133 (100), 131 (11), 129 (12), 119 (13), 118 (17),
117 (17), 111 (16), 105 (12), 91 (16), 77 (14), 70 (80). C21H27NOS
(341.52): calcd. C 73.86, H 7.97, N 4.10; found C 73.48, H 7.67, N
3.99.
the sulfoximine o-D-22 (36 mg, 95%) with a D content of Ն95%
(1H NMR, o,oЈ-Ph) as a colorless oil.
(+)-(1S,6S)-6-Benzyl-1-(2-ethylphenyl)-3,4,5,6-tetrahydro-1λ4-1,2-
thiazine 1-Oxide (26): nBuLi (0.29 mL of 1.6 m in n-hexane,
0.47 mmol) was added dropwise at –50 °C to a solution of the sul-
foximine 20 (127 mg, 0.42 mmol) in THF (10 mL). After the mix-
ture had been stirred for 10 min at room temperature, whereupon
it attained a red color, it was treated at –78 °C with MeI (90 mg,
0.64 mmol) and stirred for 3 h at this temperature. The mixture was
then poured into saturated aqueous NH4Cl (20 mL) and extracted
with EtOAc (3ϫ 20 mL). The combined organic phases were dried
(+)-(1S,6S)-6-(2,4,6-Trimethylbenzyl)-1-(2-trimethylsilylphenyl)-
3,4,5,6-tetrahydro-1λ4-1,2-thiazine 1-Oxide (22): Treatment of the
sulfoximine 5 (380 mg, 1.16 mmol) with ClSiMe3 (190 mg,
1.30 mmol) as described in GP 2 and chromatography (EtOAc)
gave the sulfoximine 22 (276 mg, 60%) with Ն98% de (1H NMR, (MgSO4) and concentrated in vacuo. Purification by chromatog-
o,oЈ-Ph) as a colorless solid; Rf = 0.64 (EtOAc); m.p. 62 °C. [α]D
=
raphy (EtOAc/MeOH 9:1) gave the sulfoximine 26 (118 mg, 90%)
+40.6 (c = 0.52 in CH2Cl2). 1H NMR (400 MHz, CDCl3): δ = 0.47 with Ն98% de (1H NMR, o,oЈ-Ph) as a colorless oil; Rf = 0.57
1
(s, 9 H, SiMe3), 1.68–1.88 (m, 2 H, CH2CH2CH2), 1.93 (s, 6 H,
2444
(EtOAc/MeOH 9:1). [α]D = +16.4 (c = 2.25 in CH2Cl2). H NMR
www.eurjoc.org
© 2011 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim
Eur. J. Org. Chem. 2011, 2431–2449